Ensysce Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 18, 2022, by Ensysce Biosciences, Inc. (Ensysce), a Delaware corporation. The report details amendments to a Securities Purchase Agreement (SPA) originally entered into on September 24, 2021, for an aggregate financing of $15 million with institutional investors. The filing specifically addresses a Second Letter Agreement dated January 16, 2022, which modifies the conversion terms of senior secured convertible promissory notes issued under the SPA.
Key Financial Metrics and Obligations
The filing does not provide revenue, profit, cash flow, or margin data as it is a current report regarding a specific transaction rather than a periodic financial statement. Key financial obligations disclosed include:
- Total Financing: $15 million aggregate principal amount of senior secured convertible promissory notes.
- Note Issuance:
- First Closing (Sept 24, 2021): $5.3 million principal for $5 million purchase price.
- Second Closing (Nov 5, 2021): $10.6 million principal for $10 million purchase price.
- Warrants Issued: Aggregate of 1,083,475 warrants to purchase common stock (361,158 at first closing; 722,317 at second closing).
- Conversion Price: The base conversion price is $5.87 per share. However, a temporary discount was applied via the Second Letter Agreement.
Material Changes and Transaction Details
The primary material change reported is the amendment of the conversion price for the outstanding notes:
- Previous Amendment: A Letter Agreement dated December 27, 2021, allowed conversion at $4.50 per share from December 28, 2021, to January 14, 2022. This period has expired.
- Current Amendment (Second Letter Agreement): Dated January 16, 2022, this agreement allows note holders to convert notes at a reduced exercise price of $3.80 per share.
- Effective Period: The $3.80 conversion price is effective from January 18, 2022, through February 11, 2022.
- Reversion: Following the February 11, 2022, deadline, the conversion price reverts to the initial $5.87 per share.
- Conditions: The Second Letter Agreement includes certain conditions the Company must satisfy, though specific details of these conditions are not enumerated in the text.
Outlook, Risks, and Contingencies
The filing indicates that the Company has registered the resale of shares issuable upon conversion of the Notes and exercise of Warrants with the SEC. The Notes and Warrants were issued unregistered under Section 4(a)(2) of the Securities Act. The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard contingencies associated with the satisfaction of conditions in the Second Letter Agreement.
Investor Verification Checklist
- Verify the specific conditions Ensysce must satisfy under the Second Letter Agreement to maintain the $3.80 conversion price.
- Confirm the total outstanding principal amount of the Notes as of the filing date to assess potential dilution if converted at the discounted rate.
- Review the Security Agreement and Patent Security Agreement (Exhibits 10.4 and 10.5) to understand the collateral securing the notes.
- Monitor the stock price relative to the $3.80 conversion price during the window ending February 11, 2022, to gauge the likelihood of conversion.